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Introduction
Although tumour cells express specific antigens they often escape immunological elimination in vivo. 1 It has been postulated that the tumour cells induce immunological tolerance through different mechanisms ranging from a defect in the induction of the anti-tumour immune response to a defect in the killing of the tumour cells by T cells. 2, 3 Tumour vaccine strategies are designed to break immunological tolerance to the tumour. Thus, a large proportion of the current clinical trials in cancer gene therapy are based on the principle of whole cell vaccination where tumour cells bearing tumour-associated antigens are modified by in vitro genetic manipulation to increase their immunogenicity, irradiated and then injected into patients suffering from cancer. Such an approach has been successful in many murine tumour vaccine models when vaccination with irradiated autologous tumour cells modified to express genes coding for co-stimulatory molecules, MHC molecules, interferons or cytokines can protect against a live challenge with wildtype (unmodified) tumour cells. 4, 5 In some immunogenic tumour models, the immune response generated by the immunisation has been fast and strong enough to treat an established tumour.
T cells need two signals for activation to take place. One signal is received through the interaction of the T cell receptor with a peptide antigen presented in a groove of an MHC molecule on the antigen-presenting cell (APC) and a second signal has to be delivered either by lymphokines such as IL-2 or through the interaction between T cell molecules (eg CD28) and co-stimulatory molecules (eg B7.1) on the APC. In the absence of a costimulatory signal, T cells will become anergic to this antigen. 6 It is therefore not surprising that a concerted effort into expressing co-stimulatory molecules such as B7.1 on tumours has been undertaken with regard to the treatment of metastatic cancer in humans. However, this approach can be deleterious in some cases. Chong and colleagues 7 have reported the detrimental effect of B7.1 and B7.2 expression on the immunogenicity of the murine K1735 cells. Here, we have compared B7.1 expressing tumour cells, in the B16-F10 model which has very poor immunogenicity, directly with hybrids and allogeneic cells as well as with autologous cells mixed with a powerful adjuvant, Provax.
Results

Production of hybrids
Hybrids between tumour cell lines and macrophages, both activated and non-activated, were achieved without any major technical difficulty. The hybrids grew well in culture in selection medium up to passage 10, could be frozen in liquid nitrogen and be revived from storage as easily as other established cell lines. Compared with B16-F10, the parent cell line, the hybrids had a more differentiated phenotype with increased melanin expression and prolongation of doubling time. Many different hybrids clones, each one with its own phenotype, were produced after fusion of the parental cell lines (see Figure 1 ). This diversity in phenotype was both observed with the auto- hybrid cells (B16-F10# C57BL/6J macrophage) and the allo-hybrid cell (B16-F10# C3H macrophage).
Flow cytometry analysis of hybrid cells
We detected the expression of MHC molecules after treatment of the hybrids cells with gamma-interferon from both parent cell lines in the allogeneic hybrid (B16-F10[H2b] # C3H macrophage [H-2k]). We noticed that the MHC class II from the C57BL/6J H-2b haplotype was expressed after fusion, whereas the parent cell line (B16-F10) did not express MHC class II and therefore we assume that expression of I-Ab was stimulated by genes or soluble proteins provided by the macrophage isolated from the C3H mice (H-2k) but surprisingly the level of I-Ak molecules, which should have been provided by the parent macrophage, was minimal ( Figure 2 ). Both allogeneic and autologous hybrids had low levels of B7.1 molecules but FACScan analysis of B7.1-expressing cells Figure 4 shows the log difference of B7.1 expression between the B7.1-expressing B16-F10 clone and the B16-F10 clone transfected with empty vector used for immunisation. The latter was negative for B7.1 expression as compared with the B7.1 expressing clone stained with an irrelevant antibody.
Tumour vaccination experiment with B7-expressing B16-F10 cells Figure 5 shows the survival curve of the groups of mice vaccinated with the B16-F10 cells transfected with empty vector and the mice vaccinated with B7-expressing B16-F10 cells. No antitumour effect was recorded using the B7.1-expressing cell vaccination (P = 0.07, HR = 2.2). Tumour vaccination experiment with B16-F10 cells mixed with an oil-in-water emulsion adjuvant Figure 6 shows the antitumour vaccine benefit conferred by the B16-F10 cells mixed with the oil adjuvant, Provax (P = 0.001, HR = 4.04). This experiment confirmed our previous report in which it was shown that this vaccine regimen was superior to vaccination with cells transfected with IL-2.
8
Comparison of autolologous versus allogeneic tumour vaccination Vaccination with allogeneic murine cells conferred a significant antitumour benefit compared with vaccination with autologous B16-F10 cells ( Figure 7 , P = 0.03, HR = 2.6). Again this experiment confirmed our previous finding. 9 
Discussion
The goal of our present report was to compare the feasibility and the antitumour activity of different whole cellbased tumour vaccines. We were particularly interested in the results of cells transfected with the B7.1 molecule in view of the negative effect described in the K1735 model, 7 as well as to look at the potential that hybrids between tumour cells and macrophages may be more powerful APC than tumour cells alone. Neither of these strategies induced any effective antitumour effect. This could be due to the poor antigenicity of the B16-F10 melanoma tumour cell. However, our experiments using allogeneic cells and autologous cells mixed with a powerful adjuvant showed that good antitumour immunity could be achieved and that protection was seen in 20 to 30% of challenges in the preventative setting. A recent report has also highlighted the superiority of the allogeneic vaccination over autologous vaccination using an antigenspecific tumour model. 10 B16 and K1735 melanoma cells have previously been found to share common tumourassociated antigens like B700 antigen. 11 At present, we do not know the shared antigen between B16 and K1735 which leads to cross-protection but this is the subject of on-going work in our laboratory.
We can only speculate on the mode of tumour antigen 
Figure 6 Tumour vaccination with B16-F10 cells mixed with an oil-in-water emulsion adjuvant. The anti-tumour vaccine benefit conferred by the irradiated B16-F10 cells mixed with the oil adjuvant, Provax, compared with vaccination with irradiated B16-F10 cells alone.
presentation provided by the vaccines made of allogeneic cells or autologous cells mixed with an appropriate adjuvant. It is tempting to suggest that in this case the presentation is mediated through cross-priming where antigens are shed from the vaccine cells and then taken up by professional APC and presented to the immune system. [12] [13] [14] Understanding the complex mechanisms of indirect antigen presentation may help the design of better tumour vaccines. However, the complexities of antigen processing can be illustrated by other experiments conducted within our group using a characterised antigen (ovalbumin) specific model. For example, Sheikh et al 15 using several delivery systems to generate antigenspecific, MHC class I-restricted cytotoxic T cells, demonstrated that there is a highly variable requirement for APC. Futhermore, while these different delivery systems are similar in their ability to generate CTL, some shunt exogenous protein into an alternative TAP-1-independent pathway as assessed by studies in knockout mice. 16 On the other hand, the fact that transfecting B7.1 into other tumour cells in different murine tumour systems other than B16 melanoma induces a protective immunity suggests the role of many factors in producing this activity. Chen and colleagues 17 have demonstrated that B7-1 expressing tumour cells are effective tumour vaccines only if the wild-type tumour cell is inherently immunogenic. In the nonimmunogenic B16-F10 model, we found that B7.1-expressing B16-F10 cells had no vaccine activity and that even the survival time of the mice vaccinated by B7+B6-F10 cells was moderately shortened, as Chong and colleagues 7 have reported in a surgical model of K1735 murine melanoma. Many factors can influence the efficacy of the B7.1-based strategy, eg the degree of B7.1 expression 18 but other factors like adhesion or integrin molecule interaction may also be critical. Direct antigen presentation to MHC class I restricted CTL specific for a tumour antigen expressed on a class I negative tumour cell occurs only after multiple vaccination with the B7-expressing tumour cells. 19 Cayeux and colleagues 14 have however shown that B7.1-expressing TS/A mammary 18 showed that both CD8 + cells and NK cells were necessary for recognition of live B16-F10 cells expressing B7.1 molecules in tumorigenicity studies. As in our own experience, they also showed that B7.1-expressing B16-F10 cells failed to induce antitumour protection against a subsequent live challenge.
Vaccination with hybrids prepared between tumour cells with either B cells or dendritic cells have been reported to induce tumour rejection: Guo and colleagues 21 have fused B cells with hepatoma cells and Gong and colleagues 22 have fused MC038, colon adenocarcinoma with dendritic cells. In our study, the hybrids between the B16-F10 cells and macrophage had no antitumour activity. We originally chose macrophages for practical reasons. First, they are easy to isolate both in humans and in mice. Second, macrophages are important APC for inducing class-I restricted CTL after vaccination with exogenous antigens 23 although the dendritic cell may be more important. 24 The lack of MHC and costimulatory molecules in the hybrids may have accounted for the lack of vaccine activity and this may explain the lack of activity of the allogeneic hybrid vaccination compared with vaccination with allogeneic K1735 melanoma cells. Taking our results with those in the literature it would seem that dendritic cells may be better for hybrid production than macrophages. In relation to hybrid production, it is imperative that the hybrid cells at least mimic dendritic cells in their antigen-presenting cell capability and in their co-stimulatory molecule expression. This was not the case with the hybrid cells we prepared as they only expressed relevant molecules after gamma-interferon treatment and the level of expression was not high. This highlights the fact that in clinical practice the potential problems caused by random fusion between tumour cells and antigen-presenting cells have to be overcome. In addition the morphological heterogeneity of the tumour/macrophage hybrid cells may lead to different clones with different immunogenicity. If one wants to go down the route of establishing hybrids in long-term culture, it may be necessary to fully characterise individual clones and expand those with high expression of immunologically relevant molecules. 25, 26 This will obviously increase the time for such a procedure both with autologous tumour cells and even with allogeneic tumour cells. The other alternative is to culture the hybrids with gamma-interferon (and maybe TNF) 27 before vaccination. The other option is to follow a more practical and clinically relevant strategy: obtain tumour cells at surgery, in parallel isolate APC (eg dendritic cells or B cells) and fuse these parent cells just before vaccination. This approach is even more relevant to non-solid tumours like leukaemia where the cancer cells are easily accessible. However, technical limitations will have to be overcome before such a proposition could be clinically practical, as the standard methods for fusion (PEG and Sendai virus) are effective only in a small percentage of the cells. We calculated that less than 1% of the cells were hybrid before the selection process in the experiments described here. Another method of cell fusion, electrofusion, is claimed to be more efficient for hybrid production. Stuhler and colleagues 28 reported good antitumour activity in the EL-4 murine model using therapeutic vaccination with hybrids produced by electrofusion from allogeneic B cells and autologous tumour cells. Clinical trials have already commenced in patients with melanoma and renal cell carcinoma using this technology. 29, 30 Our experiments suggest that in human solid tumours, which are relatively nonimmunogenic, vaccination with allogeneic or autologous cells with a strong adjuvant may be effective at inducing antitumour responses. It is of interest that a recent randomised clinical study showed a statistical benefit in the group of patients receiving a therapeutic tumour vaccine which consisted of autologous irradiated tumour cells, prepared by disruption of the colon tumour removed at surgery, mixed with BCG. 31 Soon the results of randomised studies based on genetically manipulated cells will follow. However, the second generation of these genetically alternative vaccine strategies may need to combine different approaches for them to be clinically successful and superior to whole cell vaccine strategies not based on genetic manipulation.
Material and methods Animals
Pathogen-free C57BL/6J mice were obtained from B&K (Hull, UK). All mice were female and immunised at the age of 6 to 12 weeks unless otherwise stated. All procedures were carried out under mild general anaesthesia and in accordance with the UK Home Office and ethical guidelines.
B16-F10 cell and K1735-M2 cell lines B16-F10 murine melanoma 32 were kindly provided by Professor Ian Hart (ICRF, London, UK) and the K1735 clonal isolate M2 murine melanoma cells (derived from C3H/He) were obtained from Dr IJ Fidler (MD Anderson Cancer Center, Houston, TX, USA). 33 The cells were grown in complete medium made of Eagle's MEM medium containing 2 mm l-glutamine, 1 × MEM nonessential amino acid (Sigma, Poole, UK), 1 mm sodium pyruvate, 1 × MEM vitamin solution (Sigma), 0.1% gentamycin (Sigma) and 5% heat inactivated foetal calf serum, in 10% CO 2 . The cells were passaged with 0.05% trypsin (Gibco, Paisley, UK) and 0.02% EDTA and were free from mycoplasma as assessed by the gene probe method (Gene-Probe, San Diego, CA, USA). Phenotyping by FASCcan analysis of the B16-F10 cells revealed that they expressed very low levels of MHC class I (H-2Kb) molecules and were MHC class II (I-Ab) and B7.1 (CD80) negative whereas K1735-M2 cells express high levels of MHC class I (H-2Kk) molecules (data not shown).
The B16-F10 mutant cell line, B16-F10 rr (a kind gift of Dr D Bennett, St George's Hospital, and Professor I Hart, St Thomas' Hospital, London, UK) is resistant to ouabain but does not grow in HAT medium. 34 It was grown routinely in the same complete medium as described above with the addition of ouabain (6 mm) and 6-thioguanine (15 g/ml) to maintain their mutant phenotypic expression.
Preparation of macrophages
Autologous and allogeneic macrophages were prepared exactly as described by Fortier. 35 In brief, 1 ml of 3% Brewer thioglycollate medium (Difco, West Moseley, UK) was injected into the peritoneum of the mice C57BL or C3H/HeN mice which were then left for 5 days. Macrophages were then collected after peritoneal lavage with 10 ml complete medium and after washing, were cultured in complete medium until fusion with the B16-F10 rr cells.
B7 plasmid preparation and transfection
The murine B7.1 expressing plasmid (pBJB7) was a gift from Dr L Lanier (DNAX, Palo Alto, CA, USA) and is based on a modified pBR322 plasmid which carries the pSV2neo (neomycin resistance) gene and also SV40/HTLV1 promoter for the B7.1 gene. The empty vector pBJempty was prepared by cutting out pBJB7 with XhoI and BamHI. Both plasmids were purified under two cycles of caesium chloride centrifugation for transfection. Transfection of B16-F10 cells with these plasmids were performed using DOTAP (Boeringer Mannheim, Lewes, UK) exactly as described by Wakeling and colleagues. 36 Hybrid cells preparation B16-F10 rr was fused with syngeneic macrophages from C57BL mice (H-2b) and allogeneic macrophages from C3H/HeN mice (H-2k) following methods described by Wakeling et al 34 and Turpeennniemi-Hujanen and colleagues 37 with few modifications. B16-F10 rr cells and peritoneal macrophages were plated in a 10-cm Petri dish at a ratio of 1:1 (10 6 each) overnight and then fused with a solution of 50% PEG (Mol wt 1000) for 1 min, washed with complete medium and then incubated for another 24 h. The cells were then harvested with trypsyn-EDTA, washed once and plated at 10 4 cells/ml in complete medium with 10 mm ouabain and HAT (1×). Control plates with macrophages alone and B16F rr cells alone were also processed in parallel. No cells survived in these control plates. 
Reagents and adjuvants
Provax (formely known as IDEC-AF), an adjuvant of the oil-in-water emulsion category was kindly provided by IDEC Pharmaceuticals (San Diego, CA, USA). The components of Provax are squalane (15% (wt/vol)), Tween 80 (0.6%) and pluronic acid L121 (3.75%) as described by Hariharan and colleagues. 38 PEG, ouabain, 6-thioguanine and the HAT medium (stock solution ×50 strength) were purchased from Sigma.
Vaccine preparation and immunisation
For vaccine preparation, B16-F10 cells were harvested with 0.02% EDTA in PBS, washed twice in PBS and resus-pended at the specified density in PBS. B16-F10 were either irradiated with 50 Gy or subjected to three cycles of freeze thawing in liquid nitrogen. Provax was mixed gently with B16-F10 cells at a ratio of two volumes of cells to one volume of adjuvant. Mice were allocated into groups (10 animals per group) and were vaccinated with a single inoculation of B16-F10 cells, with or without adjuvant, in a total volume of 200 l (100 l in the tail and 50 l subcutaneously on two abdominal sites).
Tumor growth in vivo
Ten days after immunisation, mice were challenged, on the right flank, with 5 × 10 5 live B16-F10 cells in 100 l PBS. This challenge dose was determined in standardisation experiments to be 100 times the TD50 (data not shown). Mice were then monitored at least every 3 days for palpable tumour, for up to 4 months. Tumor size were recorded from two caliper measurements of perpendicular diameters. The experiment was terminated for individual mice when a tumor reached 1.5 cm in one of the diameters, when severe ulceration or bleeding occurred or the animal died.
Statistical analysis
Survival following immunisation and tumor cell challenge were compared with the log-rank test (two-tailed P value) using the GraphPad Prism statistical package (San Diego, CA, USA). The significance between survival curves was defined as a P value of less than 0.05.
